Bendamax25 mg/vial

Bendamax is an alkylating antineoplastic agent used, under the supervision of an oncologyspecialist, in the following settings:

Established / FDA-approved uses

• Chronic lymphocytic leukemia (CLL): Bendamax is approved for the treatment ofCLL. (Efficacy relative to first-line therapies such as fludarabine-based regimens has not been established.)
• Indolent B-cell non-Hodgkin lymphoma (NHL): Bendamax is approved forpatients whose disease has progressed during, or within six months of, treatment with rituximab or arituximab-containing regimen.

Guideline-supported / combination and off-label uses

• Multiple myeloma: Bendamax is used in some regimens (in combination withcorticosteroids and/or other antimyeloma agents) as an off-label/guideline-referenced option, generally after otherstandard options have been considered.
• Relapsed/refractory Hodgkin and other B-cell lymphomas: Bendamax is sometimesused off-label as part of multi-agent chemotherapy combinations, based on clinical trial and guideline experience,when standard regimens are not suitable.

Any use of Bendamax outside the two FDA-approved indications above should be individualizedby a qualified oncology specialist based on the specific clinical situation.

Bendamax is a bifunctional alkylating chemotherapy agent that combines structural features ofnitrogen mustard alkylators with a benzimidazole ring. It is given by intravenous infusion in cycles, exclusivelyunder the supervision of a physician experienced in the use of cytotoxic chemotherapy, for the treatment of certainlymphoid malignancies including chronic lymphocytic leukemia and specific types of non-Hodgkin lymphoma.

Bendamax is not an outpatient self-administered medicine; dosing, scheduling, and monitoringmust be individualized by an oncology specialist, with regular laboratory monitoring throughout treatment.

Pharmacodynamics

Bendamustine forms electrophilic alkyl groups that covalently cross-link DNA at the N7 position ofguanine, producing interstrand DNA cross-links. This DNA damage is extensive and repaired relatively slowly, leadingto cell-cycle arrest and apoptosis in both actively dividing and resting (non-proliferating) lymphocytes, whichcontributes to its activity in indolent lymphoid malignancies.

Pharmacokinetics

• Protein binding: approximately 94–96%, mainly to albumin.
• Metabolism: primarily hepatic, largely via hydrolysis, with minor oxidative metabolism throughCYP1A2 to active metabolites (including gamma-hydroxy-bendamustine and N-desmethyl-bendamustine).
• Elimination half-life: approximately 30–40 minutes for the parent compound.
• Excretion: mainly via feces, with a smaller proportion recovered in urine.

Bendamax is for intravenous infusion only and must be prepared and administered by trainedhealthcare personnel using appropriate cytotoxic handling precautions (protective clothing, safe disposal).

• The reconstituted/diluted solution of Bendamax is given as an IV infusion, typically overabout 30–60 minutes depending on the product/formulation and indication (some ready-to-use liquid formulations allowshorter infusion times per their specific product labeling).
• Bendamax must be administered through a securely placed, free-flowing intravenous line;extravasation can cause local tissue damage, so the infusion site should be monitored throughout the infusion.
• Do not mix or co-administer Bendamax in the same infusion line with other medicinalproducts.
• Premedication (e.g., antipyretics, antihistamines, and/or corticosteroids) may be used in later cycles forpatients who experienced infusion reactions with earlier cycles, per institutional protocol.

Clinically significant interactions with Bendamax include:

• CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin): may increase exposure toBendamax and decrease exposure to its active metabolites; use with caution and monitor closelyfor increased toxicity.
• CYP1A2 inducers (e.g., omeprazole, cigarette smoke): may decrease exposure toBendamax; avoid concurrent use with strong inducers when possible.
• Myelosuppressive or immunosuppressive drugs: concurrent use with other bone-marrow-suppressingagents can increase the risk of severe cytopenias (see Precautions and Warnings).
• Live vaccines: should generally be avoided during and for a period after treatment withBendamax because of the risk of disseminated infection in an immunosuppressed patient.

The most common adverse effects associated with Bendamax include:

Serious but less common effects of Bendamax — including severe infusion/anaphylacticreactions, tumor lysis syndrome, severe skin reactions (Stevens-Johnson syndrome/toxic epidermal necrolysis), andsecondary malignancies — are described in full under Precautions and Warnings.

Pregnancy

Bendamax is contraindicated in pregnancy. As a cytotoxic alkylating agent, it can cause fetalharm and has shown teratogenic and embryo-fetal toxic effects in animal reproduction studies. Women of reproductivepotential should use effective contraception during treatment with Bendamax and for a periodafter the last dose; male patients should also use effective contraception, as advised by their physician, given thegenotoxic potential of Bendamax. If pregnancy occurs during treatment, the patient should beadvised of the potential risk to the fetus and referred promptly for specialist counseling.

Lactation

It is not known whether Bendamax passes into human breast milk. Because of the potential forserious adverse effects in a breastfeeding infant, breastfeeding should be discontinued during treatment withBendamax and is not recommended for a period after the last dose, on the advice of the treatingphysician.

Bendamax carries important warnings and requires close specialist monitoring:

• Myelosuppression: dose-limiting bone marrow suppression (neutropenia, thrombocytopenia, anemia)is common with Bendamax; complete blood counts should be monitored regularly, with dosemodification, treatment delay, or growth-factor support per protocol as needed.
• Infusion reactions: Bendamax can cause infusion reactions, including raresevere or anaphylactic reactions, which may worsen with subsequent cycles; premedication may be used in patientswith prior reactions, per protocol.
• Tumor lysis syndrome (TLS): particularly in patients with high tumor burden; appropriateprophylactic measures (adequate hydration and, when indicated, uric-acid-lowering therapy) and monitoring should beused with Bendamax.
• Skin reactions: rare but serious, sometimes fatal skin reactions, including Stevens-Johnsonsyndrome and toxic epidermal necrolysis, have been reported with Bendamax; treatment should bediscontinued and the patient evaluated promptly if a severe skin reaction develops.
• Secondary malignancies: cases of myelodysplastic syndrome, myeloproliferative disorders, acutemyeloid leukemia, and other secondary cancers have been reported after treatment with Bendamaxand other alkylating agents; long-term follow-up is advised.
• Infection risk: Bendamax-related immunosuppression increases susceptibilityto infection; monitor for fever or other signs of infection.
• Extravasation: can cause local tissue damage; administer Bendamax via asecurely placed intravenous line with extravasation-management measures available.
• Hepatic/renal impairment: use with caution and closer monitoring; avoid in significant impairment(see Dosage and Administration).
• Specialist use only: Bendamax requires dosing and administrationindividualized by an oncology specialist and is not an outpatient self-administered medicine.

There is no specific antidote for Bendamax overdose. Overdose would be expected to worsen theknown toxicities of Bendamax, particularly severe myelosuppression and gastrointestinaltoxicity. If an overdose of Bendamax is suspected, seek immediate medical attention or contactemergency services/a poison control center; management is supportive, with close monitoring of blood counts andorgan function in a hospital setting, as directed by the treating physician.

• Elderly: Bendamax has been used in elderly patients; no major differences inefficacy have been consistently reported, but closer monitoring for toxicity, particularly myelosuppression andinfections, is advised because of age-related organ function decline.
• Renal impairment: use of the conventional Bendamax powder formulation isgenerally avoided when creatinine clearance is below 40 mL/min; use with caution in milder impairment (see Dosage andAdministration).
• Hepatic impairment: avoid Bendamax in moderate-to-severe hepatic impairment;use with caution in mild impairment.
• Pediatric patients: safety and efficacy of Bendamax have not beenestablished (see Pediatric Uses).
• Pregnancy and lactation: see Pregnancy and Lactation section.

The lyophilized powder form of Bendamax must be reconstituted and further diluted by trainedhealthcare personnel using strict aseptic technique before intravenous administration:

• The powder is reconstituted with the diluent specified in the product labeling (commonly sterile water forinjection), swirled gently until fully dissolved (not shaken vigorously).
• The reconstituted Bendamax solution is then further diluted in an appropriate infusion fluid(such as 0.9% sodium chloride) to the volume specified for infusion.
• Ready-to-use liquid formulations of Bendamax (where available) still require dilution intoan infusion bag per their specific product labeling but do not require the initial reconstitution step.
• Prepared Bendamax solutions should be used within the time limits specified by themanufacturer and protected from light as directed; discard any unused portion appropriately as cytotoxic waste.

D